Zacks Investment Research downgraded shares of IMMUNOGEN INC (IMGN) from OUTPERFORM to NEUTRAL on January 27, 2014, with a target price of $18.20.
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on IMMUNOGEN INC (IMGN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment